Envoy Medical, Inc. (COCH) - 10-Q Summary
Business Context and Reporting Period
Reporting Period: Quarter and six months ended June 30, 2026.
Business Overview: Envoy Medical is a hearing health company focused on fully implanted hearing solutions. Its primary focus is the development of the investigational Acclaim® Cochlear Implant (Acclaim CI), which received FDA Breakthrough Device Designation in 2019. The company also maintains the Esteem® Fully Implanted Active Middle Ear Implant (Esteem FI-AMEI), the only FDA-approved fully implanted active hearing device, though commercial traction has been limited due to reimbursement challenges.
Development Status: As of June 30, 2026, the pivotal clinical trial for the Acclaim CI has enrolled all 56 patients, with all patients completing activation visits by April 16, 2026. The first module of the Premarket Approval (PMA) application was submitted to the FDA on June 30, 2026. The company anticipates FDA approval in the second half of 2027 or first half of 2028.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|
| Net Revenues | $51 | $90 | $124 |
| Net Loss | $(5,982) | $(10,333) | $(10,688) |
| Net Loss Attributable to Common Stockholders | $(7,272) | $(12,973) | $(13,178) |
| Operating Loss | $(5,569) | $(11,528) | $(10,177) |
| Research & Development Expenses | $3,132 | $6,774 | $5,233 |
| Cash and Cash Equivalents (End of Period) | $19,679 | $19,679 | $5,287 |
| Accumulated Deficit | $(326,369) | $(326,369) | $(297,912) |
Liquidity: Cash increased from $3.7 million at year-end 2025 to $19.7 million at June 30, 2026, primarily due to net proceeds of $27.8 million from the February 2026 Offering. Management states that existing cash is not sufficient to fund operations through at least one year from the filing date without additional financing.
Material Changes vs. Prior Period
- Revenue: Net revenues decreased 34.6% ($27k) for the quarter and 27.4% ($34k) for the six months compared to the prior year periods, reflecting minimal commercial activity for the Esteem FI-AMEI.
- Operating Expenses: Total operating expenses increased 9.2% for the quarter and 12.8% for the six months.
- R&D: Increased 26.0% (quarter) and 29.4% (six months) driven by the expansion of the Acclaim CI clinical trial to the Second Stage and PMA application preparation.
- Sales & Marketing: Decreased 49.9% (quarter) and 52.0% (six months) due to the reallocation of field clinical engineers to R&D activities.
- Other Income/Expense: Significant volatility due to warrant liabilities.
- Private Warrants: A loss of $838k (quarter) and gain of $1.17M (six months) resulted from the remeasurement of Investor Warrants issued in late 2025.
- Related Party Interest: Interest expense dropped to zero for the 2026 periods following the extinguishment of Term Loans in August 2025.
- Capital Structure: The company completed a February 2026 Offering raising $27.8 million in net proceeds, issuing 47.9 million shares of Class A Common Stock and 27.1 million pre-funded warrants.
Outlook, Risks, and Contingencies
- Going Concern: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern. Management plans to alleviate this through potential warrant exercises or other financing, but there is no assurance of success.
- Regulatory Timeline: The company expects to submit the final PMA application in early Q2 2027, with an FDA decision anticipated in H2 2027 or H1 2028. Delays or a request for a panel review could push approval to 2028.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2026, citing material weaknesses in risk assessment, accounting policies, and IT general controls. Remediation is ongoing.
- Legal Proceedings: The company is defending a lawsuit filed by Atlas Merchant Capital SPAC Fund I LP alleging damages of approximately $9.4 million related to share redemption restrictions. The company believes the suit is meritless.
- Preferred Stock Dividends: The company has accrued unpaid dividends on Series A Preferred Stock totaling $6.4 million as of June 30, 2026. Payment is deferred due to net tangible asset thresholds.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash exhaustion and the status of any new financing discussions, given the "substantial doubt" disclosure.
- Warrant Liability Volatility: Monitor the fair value of private and public warrants, as fluctuations significantly impact reported net loss and equity.
- Clinical Trial Milestones: Track the completion of 12-month follow-up visits for the 56 Acclaim CI patients and the submission of subsequent PMA modules.
- Internal Control Remediation: Review future filings for progress on remediating the identified material weaknesses in internal controls over financial reporting.
- Legal Exposure: Monitor the status of the Atlas Merchant Capital litigation and any potential settlement or judgment impacts.